The main obstacle to a malaria vaccine: the malaria parasite.
The challenge to development of a malaria vaccine will be the variability of the sequences of target antigens. We discuss the variability in the T cell epitopes on the circumsporozoite protein of Plasmodium falciparum and the rapid selection of mutants after immunization with a protein from the asexual erythrocytic stage of P. knowlesi.
Miller
L H
LH
Laboratory of Parasitic Diseases, NIAID, Bethesda, MD 20892.
Good
M F
MF
D000818:Animals; D000940:Antigenic Variation; D000953:Antigens, Protozoan / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D009154:Mutation; D010961:Plasmodium / Q000276:immunology*; D010963:Plasmodium falciparum / Q000276:immunology; D015800:Protozoan Proteins; D013601:T-Lymphocytes / Q000276:immunology; D014612:Vaccines / Q000276:immunology*
D000953:Antigens, Protozoan; D000954:Antigens, Surface; D015800:Protozoan Proteins; D014612:Vaccines; C041595:circumsporozoite protein, Protozoan